PTC Therapeutics Inc
Research PTC Therapeutics Inc (PTCT) on Bullrun: market cap USD 6.12B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTCT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.12B
- Financial periodQ2 2026
- RevenueUSD 360.52M
- Net incomeUSD 83.50M
- Free cash flowUSD 121.97M
- Gross margin94.5%
Valuation Snapshot
latest market cap is USD 6.12B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.73B | USD 683.00M | USD 702.34M | 97.3% | 7.78 | USD 984.65M | USD 286.63M | -USD 205.31M |
| FY2024 | USD 806.78M | -USD 363.30M | -USD 114.19M | 92.9% | -4.73 | USD 779.71M | USD 285.41M | -USD 1.10B |
| FY2023 | USD 937.82M | -USD 626.60M | -USD 186.86M | n/a | -8.37 | USD 594.00M | USD 284.21M | -USD 818.56M |
| FY2022 | USD 698.80M | -USD 559.00M | -USD 388.67M | n/a | -7.79 | USD 279.83M | USD 571.72M | -USD 347.09M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.12B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.19B | 9.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.51B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.79B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.82B | n/a | n/a | n/a |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PTC Therapeutics Inc's market cap?
PTC Therapeutics Inc's market capitalization is USD 6.12B.
What does PTC Therapeutics Inc do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.